Progress DNDi-5561, a selected aminopyrazole compound, to Phase I clinical trials and realize some activities including formulation development, drug product manufacture and start single ascending dose stage of first-in-human.
last phase of drug development
updated 31 Aug 2019
DNDI-5561 is the most advanced compound of the aminopyrazole series. DNDi developed the series from a single high-throughput screening hit, which was originally identified in an in vitro screen of Pfizer’s compound library. A hit-to-lead project conducted by DNDi produced improved leads with activity in animal models of leishmaniasis. The optimization of these leads to produce DNDI-5561 was achieved in a partnership between DNDi, Takeda Pharmaceutical Company Limited, and the GHIT Fund.
Get our latest news, personal stories, research articles, and job opportunities.